Capsugel to acquire Xcelience and Powdersize
Powdersize brings micronization capabilities that augment Capsugel’s formulation design services and premier bioavailability enhancement technology platform.
Capsugel, Xcelience and Powdersize have announced that the three companies have entered into a definitive agreement under which Capsugel will acquire both Xcelience and Powdersize. The transaction, which is subject to regulatory approval, will further enhance Capsugel’s position as a leading provider of innovative dosage forms and solutions to healthcare customers around the world.
"The additions of Xcelience and Powdersize accelerate Capsugel's strategy to expand our service offerings through continued investments in new capabilities and technologies,” said Guido Driesen, President and CEO of Capsugel. "The expertise and high levels of service that we gain in this transaction will make us an even stronger, more-differentiated partner as we collaborate with pharmaceutical companies to bring better medicines to patients."
Xcelience's and Powdersize's key capabilities augment Capsugel’s model of advancing customer products through an integrated approach to the design, development and manufacture of dosage forms. As a result of this transaction, Capsugel will add:
“We are ready to take Xcelience to the next level, and Capsugel’s global scale, commitment to science and engineering, and technology breadth and depth make it the right partner to get us there,” said Derek Hennecke, President and CEO of Xcelience. “Our collective customers will have access to a robust suite of design and development capabilities, as well as best-in-class clinical supply solutions and commercial manufacturing of innovative dosage forms.”
“We are thrilled to join forces with Capsugel,” says Wayne Sigler, CEO of Powdersize. “Our capabilities in particle-size reduction are a natural fit with Capsugel’s bioavailability enhancement suite of technologies and services. Our clients will benefit from the capabilities that the combined entity can now offer.”
Upon completion of the transaction, both Xcelience and Powdersize will be integrated with Capsugel’s Dosage Form Solutions business unit, which has built a premier offering in bioavailability enhancement, a complete range of modified release solutions and a growing suite of applications in other areas, including bio-therapeutics, inhalation and pediatric formulations.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance